Study Evaluating Intravenous CMD-193 in Subjects With Advanced Malignant Solid Tumors

Wyeth

Status and phase: Terminated; Phase 1

Conditions: Neoplasms

Treatments: Drug: CMD-193

Study type: Interventional

Funder types: Industry

Identifiers

NCT00257881

3152K1-101

Details and patient eligibility

About

The primary purpose of this study is to evaluate the safety, tolerability, and maximum tolerated dose (MTD) of CMD-193 administered intravenously (IV) to subjects with advanced malignant tumors. The secondary purpose is to obtain preliminary information on the pharmacokinetics and antitumor activity of IV CMD-193.

Sex: All

Ages: 20 to 74 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Malignant solid tumor progressed, or no standard treatment available
• Tumor expression of Lewis Y antigen

Exclusion criteria

• Cancer therapy within 28 days before enrollment
• Pregnant or breastfeeding women
• Unstable or serious concurrent medical conditions

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)